NASDAQ:KALV

KalVista Pharmaceuticals (KALV) Stock Forecast, Price & News

$10.00

-0.08 (-0.79%)

(As of 06/2/2023 ET)

Compare

Today's Range: $9.99
▼
$10.26
50-Day Range: $6.61
▼
$10.57
52-Week Range: $4.12
▼
$17.06

Volume: 143,163 shs
Average Volume: 294,665 shs
Market Capitalization: $341.70 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.33

KalVista Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 93.3% Upside
$19.33 Price Target
Short Interest: Bearish
15.76% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.57
Upright™ Environmental Score
News Sentiment: 1.00
Based on 3 Articles This Week
Insider Trading: Selling Shares
$124,398 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.61) to ($3.07) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

534th out of 983 stocks

Pharmaceutical Preparations Industry

262nd out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
KalVista Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.33, KalVista Pharmaceuticals has a forecasted upside of 93.3% from its current price of $10.00.
Amount of Analyst Coverage
KalVista Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
15.76% of the float of KalVista Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
KalVista Pharmaceuticals has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.
Change versus previous month
Short interest in KalVista Pharmaceuticals has recently increased by 4.27%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
KalVista Pharmaceuticals does not currently pay a dividend.
Dividend Growth
KalVista Pharmaceuticals does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
KalVista Pharmaceuticals has received a 76.75% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for KalVista Pharmaceuticals is -0.57.

2.8

News and Social Media Coverage

News Sentiment
KalVista Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for KalVista Pharmaceuticals this week, compared to 2 articles on an average week.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, KalVista Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $124,398.00 in company stock.
Percentage Held by Insiders
Only 8.30% of the stock of KalVista Pharmaceuticals is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for KalVista Pharmaceuticals are expected to grow in the coming year, from ($3.61) to ($3.07) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of KalVista Pharmaceuticals is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of KalVista Pharmaceuticals is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
KalVista Pharmaceuticals has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Receive KALV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KALV Stock News Headlines

June 2, 2023 | finance.yahoo.com

KalVista Pharmaceuticals to Present Data at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)

May 31, 2023 | finance.yahoo.com

KalVista Pharmaceuticals to Present at Jefferies Global Healthcare Conference

June 3, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

May 23, 2023 | finance.yahoo.com

KalVista Pharmaceuticals to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day Virtual Conference

May 21, 2023 | americanbankingnews.com

Christopher Yea Sells 2,604 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

May 21, 2023 | americanbankingnews.com

Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells 5,627 Shares of Stock

May 8, 2023 | finance.yahoo.com

KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop

April 27, 2023 | finance.yahoo.com

KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop

June 3, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

April 24, 2023 | americanbankingnews.com

KalVista Pharmaceuticals' (KALV) "Buy" Rating Reaffirmed at Needham & Company LLC

April 22, 2023 | msn.com

Needham Reiterates KalVista Pharmaceuticals (KALV) Buy Recommendation

April 20, 2023 | finance.yahoo.com

Wall Street Analysts See a 145.38% Upside in KalVista Pharmaceuticals, Inc. (KALV): Can the Stock Really Move This High?

April 19, 2023 | finance.yahoo.com

Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

April 14, 2023 | americanbankingnews.com

FY2023 EPS Estimates for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Increased by Cantor Fitzgerald

April 13, 2023 | americanbankingnews.com

Cantor Fitzgerald Reiterates Overweight Rating for KalVista Pharmaceuticals (NASDAQ:KALV)

April 13, 2023 | americanbankingnews.com

KalVista Pharmaceuticals (NASDAQ:KALV) Given Overweight Rating at Cantor Fitzgerald

April 12, 2023 | finance.yahoo.com

Here's Why You Can Add KalVista (KALV) Stock to Your Portfolio

April 12, 2023 | finance.yahoo.com

KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference

April 4, 2023 | finance.yahoo.com

Wall Street Analysts Think KalVista Pharmaceuticals, Inc. (KALV) Could Surge 145.98%: Read This Before Placing a Bet

April 1, 2023 | americanbankingnews.com

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update

March 22, 2023 | finance.yahoo.com

KalVista Pharmaceuticals, Inc. (KALV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

March 10, 2023 | msn.com

Suvretta Capital Management Now Owns 5.30% of Kalvista Pharmaceuticals (KALV)

March 3, 2023 | finance.yahoo.com

Wall Street Analysts See a 155.32% Upside in KalVista Pharmaceuticals, Inc. (KALV): Can the Stock Really Move This High?

February 27, 2023 | marketwatch.com

Hereditary Angioedema Treatment Market Size, Share, Outlook and Forecast to 2028 with Top Countries Data

February 27, 2023 | finance.yahoo.com

KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

February 16, 2023 | finance.yahoo.com

KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology

February 16, 2023 | businesswire.com

KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology

See More Headlines

KALV Price History

30 days | 90 days | 365 days | Advanced Chart

KALV Company Calendar

Last Earnings: 3/09/2023
Today: 6/02/2023
Next Earnings (Estimated): 7/06/2023
Fiscal Year End: 4/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KALV
CUSIP: N/A
CIK: 1348911
Web: www.kalvista.com
Phone: 857-999-0075
Fax: 866-553-3269
Employees: 70
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $19.33
High Stock Price Forecast: $22.00
Low Stock Price Forecast: $16.00
Forecasted Upside/Downside: +93.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-82,340,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -53.53%
Return on Assets: -48.23%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.56
Quick Ratio: 16.55

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.54 per share
Price / Book: 1.33

Miscellaneous

Outstanding Shares: 34,170,000
Free Float: 31,333,000
Market Cap: $341.70 million
Optionable: Not Optionable
Beta: 1.11

Key Executives

Mr. Thomas Andrew Crockett M.B.A. (Age 48)
CEO & Director
Comp: $980.25k

Mr. Benjamin L. Palleiko (Age 57)
Chief Bus. Officer & CFO
Comp: $722.83k

Dr. Christopher M. Yea Ph.D. (Age 59)
Chief Devel. Officer
Comp: $664.28k

Dr. Edward P. Feener Ph.D. (Age 63)
Chief Scientific Officer

Jarrod Aldom
VP of Corp. Communications

Ms. Rachel M. Morten
Sr. VP of Regulatory Affairs & QA

Dr. Michael D. Smith Pharm.D. (Age 44)
Sr. VP of Devel.

Dr. Paul K. Audhya M.B.A. (Age 51)
M.D., Chief Medical Officer

Mr. Stephen Donnelly
Director of Fin. and Company Sec.

Mr. John B. McKune (Age 47)
VP of Fin.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KALV Stock - Frequently Asked Questions

Should I buy or sell KalVista Pharmaceuticals stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for KalVista Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KALV shares.
View KALV analyst ratings or view top-rated stocks.
What is KalVista Pharmaceuticals' stock price forecast for 2023?: 4 brokers have issued 1-year price targets for KalVista Pharmaceuticals' stock. Their KALV share price forecasts range from $16.00 to $22.00. On average, they expect the company's stock price to reach $19.33 in the next twelve months. This suggests a possible upside of 93.3% from the stock's current price.
View analysts price targets for KALV or view top-rated stocks among Wall Street analysts.
How have KALV shares performed in 2023?: KalVista Pharmaceuticals' stock was trading at $6.76 at the beginning of the year. Since then, KALV stock has increased by 47.9% and is now trading at $10.00.
View the best growth stocks for 2023 here.
When is KalVista Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, July 6th 2023.
View our KALV earnings forecast.
How were KalVista Pharmaceuticals' earnings last quarter?: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) released its earnings results on Thursday, March, 9th. The specialty pharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.22.
What ETFs hold KalVista Pharmaceuticals' stock?: ETFs with the largest weight of KalVista Pharmaceuticals (NASDAQ:KALV) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).

What other stocks do shareholders of KalVista Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other KalVista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP) and Pfizer (PFE).
What is KalVista Pharmaceuticals' stock symbol?: KalVista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."
Who are KalVista Pharmaceuticals' major shareholders?: KalVista Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Suvretta Capital Management LLC (5.80%), Boxer Capital LLC (4.83%), Great Point Partners LLC (4.68%), BlackRock Inc. (4.56%), Saturn V Capital Management LLC (3.28%) and Geode Capital Management LLC (1.37%). Insiders that own company stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Edward P Feener, Miami Jewish Federatio Greater, Michael David Smith, Paul K Audhya and Thomas Andrew Crockett.
View institutional ownership trends.
How do I buy shares of KalVista Pharmaceuticals?: Shares of KALV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is KalVista Pharmaceuticals' stock price today?: One share of KALV stock can currently be purchased for approximately $10.00.
How much money does KalVista Pharmaceuticals make?: KalVista Pharmaceuticals (NASDAQ:KALV) has a market capitalization of $341.70 million. The specialty pharmaceutical company earns $-82,340,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis.
How can I contact KalVista Pharmaceuticals?: KalVista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The official website for the company is www.kalvista.com. The specialty pharmaceutical company can be reached via phone at 857-999-0075, via email at ir@kalvista.com, or via fax at 866-553-3269.

This page (NASDAQ:KALV) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial